Apheresis Industry Outlook: Advanced blood component therapies transform precision healthcare through 2036

Industry Overview:  

The global Apheresis market brought in roughly USD 4.74 billion globally in 2025 and should reach around USD 5.12 billion in 2026, growing 8.0%. Growth is driven by increasing prevalence of autoimmune disorders, hematological diseases, neurological conditions, and rising demand for plasma-derived therapies worldwide. The growing adoption of therapeutic plasma exchange, expanding blood donation programs, increasing demand for immunoglobulin therapies, and advancements in automated blood separation technologies are significantly boosting market expansion. Rising investments in transfusion medicine, oncology care, regenerative medicine, and plasma fractionation infrastructure are further strengthening global demand for advanced apheresis systems across hospitals, blood centers, and specialty clinics.

Industry Insights: Scale, Segments, and Shifts  

• Market Size & Growth: The global Apheresis market is projected to reach USD 10.87 billion by 2036, registering a CAGR of 7.8% between 2026 and 2036. 

• Segment Analysis: Disposable consumables account for nearly 59% of the global market owing to recurring procedural demand, stringent infection control requirements, and single-use safety protocols in blood collection and therapeutic procedures. That said, therapeutic apheresis procedures are anticipated to witness the fastest growth due to increasing treatment of neurological disorders, autoimmune diseases, thrombotic conditions, and hematological malignancies.

• Regional Highlights: North America holds approximately 43% of the global market share in 2025, supported by advanced transfusion medicine infrastructure, growing plasma collection networks, high adoption of therapeutic apheresis, and favorable reimbursement systems. Europe continues expanding through increasing clinical adoption and blood donation programs, while Asia Pacific is witnessing rapid growth owing to expanding healthcare infrastructure, rising awareness of plasma therapies, and increasing investments in blood collection facilities.

• Competitive Landscape: The market is moderately consolidated with key players including Terumo Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation, Fresenius Medical Care AG, and Asahi Kasei Medical Co., Ltd. Companies in the space are prioritizing automated blood separation technologies, digital procedure monitoring, next-generation disposable systems, and strategic collaborations with hospitals and blood centers.

Factors Shaping the Next Decade

Market Gaps / Restraints: High capital investment required for advanced apheresis equipment, dependence on trained healthcare professionals, limited reimbursement coverage in developing economies, and procedure-related operational complexities continue to restrain wider adoption. Supply shortages of plasma donors and disposable kits also pose periodic challenges to market growth.

Key Trends and Innovations: The industry is moving fast on fully automated apheresis platforms, artificial intelligence-assisted procedure optimization, continuous-flow blood separation technologies, personalized therapeutic plasma exchange, next-generation membrane filtration systems, closed-loop extracorporeal circulation technologies, digital donor management platforms, and remote equipment monitoring systems. Manufacturers are increasingly integrating intelligent workflow management to improve procedural efficiency and patient safety.

Potential Opportunities: Expansion of plasma fractionation facilities, increasing demand for cell and gene therapies, growth of immunotherapy, rising prevalence of chronic neurological disorders, personalized medicine, regenerative medicine, and expanding blood donation infrastructure should open up substantial growth opportunities over time. Growing utilization of apheresis in oncology and rare disease management will further strengthen market demand.

Recent Industry Updates: 

• June 2025, Terumo Corporation expanded its automated blood component collection portfolio with advanced apheresis technologies designed to improve donor comfort and collection efficiency. 

• April 2025, Haemonetics introduced enhanced digital workflow solutions supporting real-time monitoring and optimization of therapeutic and donor apheresis procedures. 

• February 2025, Fresenius Medical Care strengthened its extracorporeal blood treatment portfolio by advancing membrane separation technologies for therapeutic plasma exchange applications.

Industry Outlook Scope: 

By Product

• Device

• Disposable

By Procedure

• Donor

• Therapeutic

• Neurological

• Blood Disorders

• Autoimmune Disorders

• Renal Disorders

• Other Therapeutic Procedures

By Application

• Plasmapheresis

• Plateletpheresis

• Leukapheresis

• Erythrocytapheresis

• Photopheresis

By Technology

• Centrifugation

• Membrane Separation

By End User

• Hospitals

• Blood Collection Centers

• Clinics

• Academic & Research Institutes

By Region

• North America

o U.S. 

o Canada

o Mexico

• Europe

o UK

o Italy

o Spain

o Germany

o France

o BENELUX

o Nordics

o Rest of Europe

• Asia Pacific

o China

o India

o Japan

o South Korea

o Southeast Asia

o Australia & New Zealand

• Middle East & Africa

o Saudi Arabia

o Other GCC

o South Africa

o Rest of Middle East & Africa

• South America

o Brazil

o Chile

o Argentia

o Rest of South America

Geographical Insights: Emerging Corridors of Growth 

Regional Overview: Europe continues expanding through strong national blood donation programs, increasing therapeutic plasma exchange procedures, and growing investments in rare disease treatment. Asia Pacific is witnessing rapid market expansion owing to rising healthcare expenditure, expanding plasma collection infrastructure, and increasing diagnosis of hematological and autoimmune disorders. The Middle East is strengthening specialized healthcare capabilities through investments in advanced hospital infrastructure, while South America is gradually increasing adoption of therapeutic apheresis across tertiary care hospitals and transfusion medicine centers.

Countries to Watch: United States continues leading the global market through extensive plasma collection infrastructure and advanced therapeutic applications. Japan remains a key innovation hub for automated blood separation technologies, while China is emerging as a high-growth market through expanding healthcare infrastructure, increasing plasma demand, and growing investments in transfusion medicine.

Regulatory Environment and Policy Support 

Government Regulations & Supportive Policies: The industry operates under the United States Food and Drug Administration Blood Establishment Regulations, European Union Medical Device Regulation (EU) 2017/745, American Association of Blood Banks Standards, International Organization for Standardization ISO 13485 Medical Device Quality Management Systems, and World Health Organization Blood Safety Guidelines, ensuring product quality, donor safety, and clinical effectiveness.

Key Government Initiatives: Programs including the World Health Organization Action Framework to Advance Universal Access to Safe Blood, United States National Blood Collection and Utilization Survey, European Union Beating Cancer Plan, Japan Healthcare Innovation Strategy, and India National Blood Transfusion Council Programme are supporting blood donation infrastructure, plasma collection expansion, advanced therapeutic procedures, and modernization of transfusion medicine services.

Competitive Landscape and Strategic Outlook:

The apheresis industry is fairly concentrated, with leading manufacturers investing in automation, digital workflow integration, advanced disposable technologies, and membrane separation innovations. Emerging companies are strengthening competitiveness through personalized therapeutic solutions, artificial intelligence-enabled procedure optimization, and compact blood separation platforms. Strategic collaborations between device manufacturers, plasma collection organizations, hospitals, and biotechnology companies are accelerating innovation as demand continues to grow for plasma-derived therapies, cell therapies, and precision transfusion medicine.

Industry Competition: 

• Terumo Corporation

• Fresenius SE & Co. KGaA

• Haemonetics Corporation

• Fresenius Medical Care AG

• Asahi Kasei Medical Co., Ltd.

• Becton, Dickinson and Company

• Macopharma SA

• Miltenyi Biotec

• Therakos LLC

• Toray Industries Inc.

• Kaneka Corporation

• B. Braun SE

• Nikkiso Co., Ltd.

• Cerus Corporation

• Baxter International Inc.

Analyst Perspective:

The apheresis industry is transitioning from conventional blood component separation toward intelligent therapeutic platforms supporting personalized medicine, advanced immunotherapies, and precision plasma collection. Over the next three to five years, automation, artificial intelligence-enabled workflow optimization, digital donor management, and next-generation membrane technologies will become primary competitive differentiators. Companies capable of delivering highly efficient, clinically validated, and digitally connected apheresis systems while expanding therapeutic applications will establish long-term leadership as demand continues to rise across hematology, neurology, oncology, and regenerative medicine.

What to Expect from Outlook:

1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global apheresis Market

2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global apheresis Market sector.

3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global apheresis Market with a forecast for the decade by both market share (%) & revenue (USD Billion). 

Frequently Asked Questions (FAQs)

Q1. What is the current size of the global apheresis industry?

Answer: The global apheresis industry was valued at USD 4.74 billion in 2025.

Q2. What is the projected market value of the apheresis industry by 2036?

Answer: The industry is projected to reach USD 10.87 billion by 2036, growing at a CAGR of 7.8% during 2026–2036.

Q3. What are the key factors driving the growth of the apheresis industry?

Answer: Major growth drivers include increasing prevalence of autoimmune and hematological disorders, rising plasma-derived therapy demand, expanding blood donation programs, advancements in automated blood separation technologies, and growing investments in transfusion medicine and regenerative healthcare.

Q4. Which product segment holds the largest share of the apheresis industry?

Answer: Disposable consumables account for approximately 59% of the global market owing to their recurring usage, infection prevention benefits, regulatory compliance requirements, and increasing number of donor and therapeutic apheresis procedures performed worldwide.

Q5. What are the major trends shaping the apheresis industry?

Answer: Key trends include fully automated apheresis systems, artificial intelligence-assisted procedure optimization, continuous-flow blood separation technologies, digital donor management, personalized therapeutic plasma exchange, advanced membrane filtration, and remote equipment monitoring.